Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel (Q37189622)

18 August 2017

title

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel (English)

1 reference

18 August 2017

0 references

0 references

anti-retroviral agent

0 references

author

Françoise Brun-Vézinet

4

object named as

Françoise Brun-Vézinet

1 reference

18 August 2017

Huldrych F Günthard

2

0 references

Bonaventura Clotet Sala

5

object named as

Bonaventura Clotet

1 reference

18 August 2017

10

Deenan Pillay

1 reference

18 August 2017

6

Scott M Hammer

1 reference

18 August 2017

8

Daniel R Kuritzkes

1 reference

18 August 2017

Martin S Hirsch

1

1 reference

18 August 2017

Jonathan M Schapiro

3

1 reference

18 August 2017

Victoria A Johnson

7

1 reference

18 August 2017

John W Mellors

9

1 reference

18 August 2017

Patrick G Yeni

11

1 reference

18 August 2017

Donna M Jacobsen

12

1 reference

18 August 2017

Douglas D Richman

13

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

Clinical Infectious Diseases

18 August 2017

published in

1 reference

18 August 2017

volume

47

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

266-285

1 reference

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1086%2F589297

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Evidence-based guidelines for cardiovascular disease prevention in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Accuracy of the TRUGENE HIV-1 genotyping kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Persistence of primary drug resistance among recently HIV-1 infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Web resources for HIV type 1 genotypic-resistance test interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Drug resistance and antiretroviral drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

21 January 2018

HIV entry inhibitors.

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Algorithms for the interpretation of HIV-1 genotypic drug resistance information

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Clinically relevant genotype interpretation of resistance to didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapte

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A new perspective on V3 phenotype prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F589297

21 January 2018

Identifiers

DOI

10.1086/589297

1 reference

release_m3b572ycvvfy7db2xbcunbktwy

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m3b572ycvvfy7db2xbcunbktwy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference